Inhaled steroids and the risk of hospitalization for asthma.

OBJECTIVE To determine if anti-inflammatory treatment for asthma reduces the risk of asthma hospitalization. DESIGN Retrospective cohort study. SETTING A health maintenance organization (HMO) in eastern Massachusetts. PARTICIPANTS Members of the HMO who were identified during the period October 1991 through September 1994 as having a diagnosis of asthma using a computerized medical record system. MAIN OUTCOME Hospitalization for asthma. RESULTS Of the 16941 eligible persons, 742 (4.4%) were hospitalized for asthma. The overall relative risk (RR) of hospitalization among those who received inhaled steroids was 0.5 (95% confidence interval [CI], 0.4-0.6) after adjustment for beta-agonist dispensing. Additional adjustment for age, race, other asthma medications, and amount and type of ambulatory care for asthma did not substantially affect the inverse relationship between use of inhaled steroids and hospitalization. Cromolyn was similarly associated with reduced risk, especially among children (RR,0.8; 95% CI, 0.7-0.9). In contrast, increasing beta-agonist use was associated with increasing hospitalization risk even after adjustment for other factors and medications. The steroid-associated protection was most marked among individuals who received the largest amount of beta-agonist. CONCLUSIONS Inhaled steroids and, to a lesser extent, cromolyn confer significant protection against exacerbations of asthma leading to hospitalization. These results support the use of inhaled steroids by individuals who require more than occasional beta-agonist use to control asthma symptoms.

[1]  R Platt,et al.  Assessment of asthma using automated and full-text medical records. , 1997, The Journal of asthma : official journal of the Association for the Care of Asthma.

[2]  I. Strannegård,et al.  Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in prevalence of asthma. , 1996, The Journal of allergy and clinical immunology.

[3]  G. O'Connor,et al.  Poverty, race, and medication use are correlates of asthma hospitalization rates. A small area analysis in Boston. , 1995, Chest.

[4]  R. Dales,et al.  Risk factors for recurrent emergency department visits for asthma. , 1995, Thorax.

[5]  E. R. Mcfadden,et al.  Perspectives in β2-agonist therapy: Vox clamantis in deserto vel lux in tenebris?**☆☆☆★★★ , 1995 .

[6]  B. Strom,et al.  Inhaled beta-adrenergic receptor agonists in asthma: more harm than good? , 1995, American journal of respiratory and critical care medicine.

[7]  A. O'Brien-Ladner.  Asthma: new insights in the management of older adults. , 1994, Geriatrics.

[8]  S. Suissa,et al.  Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. , 1994, The European respiratory journal.

[9]  M. Skorodin.  Pharmacotherapy for asthma and chronic obstructive pulmonary disease. Current thinking, practices, and controversies. , 1993, Archives of internal medicine.

[10]  D. Postma,et al.  A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. , 1992, The New England journal of medicine.

[11]  Alfred O. Berg,et al.  Clinical Guidelines And Primary Care Guidelines For The Diagnosis And Management Of Asthma , 2012 .

[12]  M. Hughes,et al.  Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. , 1992, The American review of respiratory disease.

[13]  P. Gergen,et al.  Inner-city asthma. The epidemiology of an emerging US public health concern. , 1992, Chest.

[14]  T. Haahtela,et al.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. , 1991, The New England journal of medicine.

[15]  A. Tattersfield,et al.  Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. , 1991, The American review of respiratory disease.

[16]  E. Juniper,et al.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. , 1990, The American review of respiratory disease.

[17]  K. Kerrebijn.  Use of topical corticosteroids in the treatment of childhood asthma. , 1990, The American review of respiratory disease.

[18]  J. Toogood.  Complications of topical steroid therapy for asthma. , 1990, The American review of respiratory disease.

[19]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[20]  P. Barnes,et al.  A new approach to the treatment of asthma. , 1989, The New England journal of medicine.

[21]  R. Strunk.  Identification of the fatality-prone subject with asthma. , 1989, The Journal of allergy and clinical immunology.

[22]  F M Chevarley,et al.  National trends in the morbidity and mortality of asthma in the US. Prevalence, hospitalization and death from asthma over two decades: 1965-1984. , 1987, Chest.

[23]  P. Newacheck,et al.  Trends in the hospitalization for acute childhood asthma, 1970-84. , 1986, American journal of public health.

[24]  T. Clark.  Inhaled corticosteroid therapy: a substitute for theophylline as well as prednisolone? , 1985, The Journal of allergy and clinical immunology.

[25]  E. Baráth,et al.  Fundamentals of Biostatistics. , 1992 .

[26]  G.O. Barnett,et al.  COSTAR—A computer-based medical information system for ambulatory care , 1979, Proceedings of the IEEE.

[27]  C. Dollery,et al.  Resistance to β‐adrenoceptor stimulants (a possible explanation for the rise in asthma deaths) , 1971, British journal of pharmacology.

[28]  R Doll,et al.  Observations on recent increase in mortality from asthma. , 1968, British medical journal.